1. Yang J, Nie J, Ma X, et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18(1):26.
2. Jabbour E, Ottmann OG, Deininger M, et al. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica. 2014;99(1):7–18.
3. US FDA. FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma [media release]. 5 Feb 2021. https://www.fda.gov/.
4. TG Therapeutics. UKONIQ™ (umbralisib): US prescribing information. 2021. https://www.tgtherapeutics.com/. Accessed 23 Feb 2021.
5. TG Therapeutics. TG Therapeutics and Rhizen Pharmaceuticals announce global agreement for development and commercialization of novel PI3K Delta selective inhibitor, TGR-1202 [media release]. 16 Aug 2012. https://ir.tgtherapeutics.com/.